Nikolova M, Bagot M, Boumsell L, Bensussan A
INSERM U448, Faculté de Médecine, Hopital Henri Mondor, Créteil, France.
Leuk Lymphoma. 2002 Apr;43(4):741-6. doi: 10.1080/10428190290016836.
Primary cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of malignant mature T-cell proliferations most often presenting as mycosis fungoides (MF) or its leukemic variant, Sezary syndrome (SS). No specific cell surface markers are presently available to distinguish the circulating malignant clone from normal lymphocytes. Using the previously established CTCL cell lines, Cou-LS and Pno, we have detected two leucocyte cell surface antigens with aberrant expression on CTCL cells. The NK-receptor (NKR) p140/KIR3DL2 normally expressed by NK and CD8+ T-cells was detected on the surface of CTCL cell lines as well as on freshly isolated CD4+PBL from SS patients. Further on, p140 marked in situ SS cells, distinguishing them from p140-negative tumor cells of patch plaque MF. SC5 is a newly described activation-related intracellular inhibitory receptor expressed on the surface of a minor PBL subset. We found that SC5 expression was significantly increased in SS cells and correlated to p140 expression. Moreover, cross-linking of SC5 molecules inhibited the malignant cell proliferation induced by anti-CD3 mAbs. The identification of these new structures on circulating SS tumor cells seems to be important both for the understanding of CTCL pathophysiology and for the clinical management of SS patients.
原发性皮肤T细胞淋巴瘤(CTCL)是一组异质性的恶性成熟T细胞增殖性疾病,最常表现为蕈样肉芽肿(MF)或其白血病变体——Sezary综合征(SS)。目前尚无特异性细胞表面标志物可用于区分循环中的恶性克隆与正常淋巴细胞。利用先前建立的CTCL细胞系Cou-LS和Pno,我们在CTCL细胞上检测到两种白细胞细胞表面抗原表达异常。自然杀伤细胞受体(NKR)p140/KIR3DL2通常由自然杀伤细胞和CD8+T细胞表达,在CTCL细胞系表面以及从SS患者新鲜分离的CD4+外周血淋巴细胞(PBL)上也被检测到。此外,p140标记原位SS细胞,将它们与斑块状MF的p140阴性肿瘤细胞区分开来。SC5是一种新描述的与激活相关的细胞内抑制性受体,在少数PBL亚群表面表达。我们发现SS细胞中SC5表达显著增加,且与p140表达相关。此外,SC5分子交联可抑制抗CD3单克隆抗体诱导的恶性细胞增殖。循环中SS肿瘤细胞上这些新结构的鉴定似乎对理解CTCL病理生理学以及SS患者的临床管理都很重要。